THRX 13.15 Theravance $THRX Hit a 52 week low of 13.05

New Post Public Reply Private Reply Replies (0) Message Board

Nov 11, 2014 at 10:19 AM

THRX 13.15 Theravance $THRX Hit a 52 week low of 13.05 Currently at 13.15 -0.29 -2.16% With a day low of 13.05 and a total volume of 75,902.

THRX Theravance Recent Headline News

Sanofi/Regeneron asthma drug successful in Phase 2 trial
Seeking Alpha - at Seeking Alpha - 2 hrs 33 mins ago

MRK: 59.44 (+0.63), AZN: 73.84 (+0.63), AMGN: 162.72 (-0.37), TEVA: 58.20 (+0.16), THRX: 13.10 (-0.34), GSK: 45.54 (+0.38), SNY: 46.68 (+0.49), REGN: 388.41 (+2.44), NVS: 92.23 (-0.40)

Theravance Biopharma Q3 Loss Widens Y/Y, Revenues Beat - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 10, 10:20AM CST
Theravance Biopharma reported a third-quarter 2014 loss of $1.72 per share.
AMAG: 34.55 (-0.36), TBPH: 18.22 (-0.10), GSK: 45.54 (+0.38), THRX: 13.10 (-0.34)

Shares of THRX Down 47.9% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Fri Nov 07, 9:10AM CST
SmarTrend identified a Downtrend for Theravance (NASDAQ:THRX) on July 18th, 2014 at $27.33. In approximately 4 months, Theravance has returned 47.93% as of today's recent price of $14.23.
THRX: 13.10 (-0.34)

5 Stocks With Big Insider Buying in November: NuStar, Huntsman and More
at The Street - Thu Nov 06, 11:45AM CST
Insiders usually buy their own shares for one reason: They think the stock is a bargain and has tremendous upside.
SCCO: 29.99 (+0.11), WRLD: 75.06 (-0.35), NS: 60.29 (+0.15), THRX: 13.10 (-0.34), HUN: 25.03 (+0.10)

Theravance to Present at Two Upcoming Investor Conferences in November
Marketwired - Wed Nov 05, 3:08PM CST
Theravance, Inc. (NASDAQ: THRX) today announced Michael W. Aguiar, President and Chief Executive Officer of Theravance, will be presenting at two upcoming investor conferences in November.
THRXV: 28.00 (+7.07), THRX: 13.10 (-0.34)

Real Money's Brian Sozzi: A Primer on Investing in Retail Stocks
at The Street - Wed Nov 05, 11:38AM CST
Some thoughts on the outlook of the retail sector and what to look for before you invest.
COH: 34.26 (+0.36), TJX: 64.01 (+0.09), NKE: 95.18 (+0.22), TGT: 65.67 (+0.15), WMT: 78.99 (-0.45), HBI: 109.91 (+0.16), THRX: 13.10 (-0.34), KORS: 68.80 (-0.35), GPS: 38.86 (+0.30), RL: 172.16 (+0.24), LULU: 43.10 (-0.20)

InsiderInsights.com Daily Round Up 11/4/14: UFI, SABA, CCI
InsiderInsights - at Seeking Alpha - Wed Nov 05, 8:31AM CST

CCI: 79.64 (-0.27), CBG: 32.08 (+0.27), HGG: 5.47 (+0.02), LLY: 68.31 (-0.04), BA: 124.99 (+0.35), MAR: 76.95 (+0.39), QNST: 4.15 (+0.03), OZRK: 36.35 (-0.25), APO: 23.20 (-0.25), STAA: 8.89 (-0.10), AMBR: 11.05 (-0.40), FSAM: 13.68 (-0.13), WRLD: 75.06 (-0.35), CPLA: 68.72 (-0.45), THRX: 13.10 (-0.34), MSFT: 48.74 (-0.15), UFI: 27.47 (-0.28), AN: 58.35 (+0.45), CRM: 63.89 (-0.56)

FDA accepts BI's Spiriva NDA for asthma
Seeking Alpha - at Seeking Alpha - Mon Nov 03, 12:06PM CST

AZN: 73.84 (+0.63), TEVA: 58.20 (+0.16), GSK: 45.54 (+0.38), THRX: 13.10 (-0.34), SNY: 46.68 (+0.49), REGN: 388.98 (+3.01), NVS: 92.23 (-0.40)

7 Old Dividend Dogs Of Healthcare Aim At 11% To 30.5% October Upsides
Fredrik Arnold - at Seeking Alpha - Mon Nov 03, 11:21AM CST

KND: 20.60 (-0.37), VIVO: 16.87 (-0.36), PETS: 13.61 (+0.06), PFE: 30.17 (-0.03), GSK: 45.54 (+0.38), MR: 31.00 (+0.40), SEM: 13.44 (-0.10), PDLI: 8.14 (+0.21), SNN: 33.69 (+0.23), AZN: 73.84 (+0.63), MRK: 59.44 (+0.63), STJ: 65.87 (+0.17), TRIB: 17.79 (+0.14), ABBV: 63.85 (+0.06), THRX: 13.10 (-0.34), SNY: 46.68 (+0.49)

Theravance (THRX) Falls on Wider-than-Expected Loss in Q3 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 03, 8:10AM CST
Theravance reported third-quarter 2014 loss of 19 cents per share.
AMAG: 34.55 (-0.36), TBPH: 18.22 (-0.10), GSK: 45.54 (+0.38), THRX: 13.10 (-0.34)

Bayer Q3 Earnings Grow Y/Y on New Product Sales, View Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 03, 8:00AM CST
Bayer's (BAYRY) earnings during the third quarter of 2014 came in at roughly $1.79 per share.
MRK: 59.44 (+0.63), AMAG: 34.55 (-0.36), THRX: 13.10 (-0.34)

Update: GSK Starts Promoting Theravance Drugs More Actively
Early Retiree - at Seeking Alpha - Sat Nov 01, 7:42AM CDT

THRX: 13.10 (-0.34), GSK: 45.55 (+0.39)

More on Theravance Q3 results
Seeking Alpha - at Seeking Alpha - Fri Oct 31, 1:03PM CDT

THRX: 13.10 (-0.34)

Theravance misses Street 3Q forecasts
Automated Insights - Fri Oct 31, 4:04AM CDT
SOUTH SAN FRANCISCO, Calif. (AP) _ Theravance Inc. (THRX) on Friday reported a third-quarter loss of $21.3 million.
THRXV: 28.00 (+7.07), THRX: 13.10 (-0.34)

Theravance's (THRX) CEO Mike Aguiar on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Oct 30, 10:27PM CDT

THRX: 13.10 (-0.34)

Theravance declares $0.25 dividend
Seeking Alpha - at Seeking Alpha - Thu Oct 30, 5:49PM CDT

THRX: 13.10 (-0.34)

Theravance Has Returned 40.7% Since SmarTrend Recommendation (THRX)
Comtex SmarTrend(R) - Thu Oct 30, 4:38PM CDT
SmarTrend identified a Downtrend for Theravance (NASDAQ:THRX) on July 18th, 2014 at $27.33. In approximately 3 months, Theravance has returned 40.69% as of today's recent price of $16.21.
THRX: 13.10 (-0.34)

Theravance (THRX) Q3 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Thu Oct 30, 3:55PM CDT

THRX: 13.10 (-0.34)

Theravance misses by $0.05, misses on revenue
Seeking Alpha - at Seeking Alpha - Thu Oct 30, 3:26PM CDT

THRX: 13.10 (-0.34)

Theravance Reports Third Quarter 2014 Financial Results
Marketwired - Thu Oct 30, 3:06PM CDT
Theravance, Inc. (NASDAQ: THRX) today reported financial results for the quarter ended September 30, 2014 and announced that its Board of Directors approved a $0.25 per share cash dividend to be paid on December 23, 2014 to stockholders of record as of the close of business on November 25, 2014. Royalties received on net sales of RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R) from Glaxo Group Limited (GSK) were $4.0 million. Net loss for the third quarter of 2014 was $21.3 million or $0.19 per diluted share. Cash, cash equivalents, marketable securities and current restricted cash totaled $316.5 million as of September 30, 2014.
THRXV: 28.00 (+7.07), THRX: 13.10 (-0.34), TBPH: 18.22 (-0.10)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

b.well and MyDirectives Streamline Access to Care Plans

Pioneering Access to Critical Care Documents Ever thought about where all those critical healthcare documents are stashed? Trust me, it’s often a mess—file cabinets, bookshelves, or stuck in some forgotten safety deposit box. Well, b.well Connected Health and MyDirectives are rolling up their sleeves to change that. They've teamed up to make advance care planning...

Watchtower Labs: New Era of AI in Military Ops

Big Moves in Military Planning Alright, folks, here's the skinny on something that's bound to shake up the military sector: Watchtower Labs has kicked the door open after its stealthy beginnings with a hefty $35 million in seed funding. Investors like Shield Capital, Conviction, and Founders Fund are throwing their weight behind this AI-powered venture that's poised to...

DaVita's Stand on HHS Kidney Plan: Innovation at Core

DaVita Stands Firm on Kidney Care Innovation The healthcare landscape's shifting undercurrent, folks, and kidney care has landed smack in the spotlight with the U.S. Department of Health and Human Services (HHS) putting forth its Kidney Care National Plan. Now, this isn't some bureaucratic mumbo-jumbo—this plan's setting the tone for kidney disease treatment across...

Pearl Meyer Bolsters Leadership Team with Key Additions

In the fast-paced world of executive advising, Pearl Meyer just cranked up the heat, announcing the addition of four seasoned managing directors to their Leadership Advisory practice. These new folks are here to shake things up, with a strong focus on executive assessment, leadership effectiveness, and organizational transformation. Strategic Moves in Leadership Adding...

Equity Alerts: Unraveling the Latest M&A Surprises

Diving Into the M&A Controversy On the bustling streets of New York, beneath the towering Empire State Building, a plot unfolds that could shake the foundations of your investments—particularly if you're holding shares in Synaptics, Eagle Financial, Victory Capital, or Centerspace. Juan Monteverde and his legal firepower from Monteverde & Associates PC are launching a...

SINEXCEL Recognized Again: Financial Growth and Innovation Rule

Repeat Honors: SINEXCEL Takes Its Place on Forbes Asia's List Picture this: a company not just making noise, but creating ripples in the ocean of energy tech. SINEXCEL, that bastion of power solutions, just snagged a spot on the Forbes Asia's Best Under A Billion list for the second time. Grab a coffee and buckle up as we dive into what makes this spectacle of...

Moises and SoundCloud Join Forces to Empower Musicians

Paving the Way for Artist Empowerment You ever wake up and feel like the music world just shifted? Like the landscape just got smoother for artists trying to juggle creativity and business without losing their minds? Well, Moises and SoundCloud teaming up might be just that seismic shift. Playing in the Big Leagues with Moises' Creative Suite Let's not fool...

AST SpaceMobile Faces Class Action Amid Investor Concerns

AST SpaceMobile: Trouble in the Cosmic Neighborhood AST SpaceMobile's recent legal scuffle signals a wake-up call. Investors, brace yourselves; the company is staring down the barrel of a class-action lawsuit. This ain’t your quiet Sunday read—it’s a full-blown securities firefight. When the DJS Law Group throws down the gauntlet, you know it's serious business....

Certification Boosts Aviation Capital's Boeing 737-10 Prospects

Nothing like a green light from the FAA to put a little extra swagger in an aircraft lessor's step, and that's exactly what's happening with Aviation Capital Group (ACG) and their big bet on Boeing's 737-10. It's like the champagne just got popped! This milestone is no minor hurdle. We're talking about the largest addition to the 737 MAX family finally giving an official...

Michaels' Report: Holiday Season Trends in 2026

Making the Holidays Personal: A New Shift As holiday lights flicker on in neighborhoods across the country, what's lighting up more than just front yards this year is a shift in consumer desires. The 2026 Michaels State of the Holiday Season Report, crafted meticulously with Morning Consult, reveals some trends that just might shake up how folks celebrate this year....